Chapter 5 Appendices
5.3 Appendix C
Drug / drug class Abbreviation
Nucleoside reverse transcriptase inhibitors
Lamivudine 3TC
Zidovudine AZT
Didanosine ddI
Abacavir ABC
Non-nucleoside reverse transcriptase inhibitors
Efavirenz EFV
Nevirapine NVP
Protease inhibitors
Ritonavir RTV
Lopinavir LPV
Lopinavir boosted with RTV LPV/r
Darunavir DRV
Tipranavir TPV
Atazanavir ATV
193
(A)
(B)
Figure 5.1 IC50 of p8MJ4-HSC compared to the IC50 of Pseudovirus 1 of Study
ID 141806 and 134102. (A) PI (B) RTI. Student’s t-determined that the mean IC50 of 2 independent experiments for the patient pseudoviruses were not significantly different from p8MJ4-HSC for each drug (p > 0.05).
0 2 4 6 8 p8MJ4-HSC 141806 134102 p8MJ4-HSC 141806 134102 p8MJ4-HSC 141806 134102 PI IC50 (nM) Pseudovirus LPV SQV NFV 0.0 0.2 0.4 0.6 0.8 1.0 p8MJ4-HSC 141806 134102 p8MJ4-HSC 141806 134102 p8MJ4-HSC 141806 134102 p8MJ4-HSC 141806 134102 p8MJ4-HSC141806 134102 p8MJ4-HSC141806 134102 RTI IC50 (nM) Pseudovirus EFV NVP 3TC AZT ABC ddI
194
(A)
(B)
Study ID Pseudovirus HIV-1 RT concentration (ng/ul)
141806 WT 0.014 184V 0.015 184V+82A 0.015 E4 0.014 134102 WT 0.014 184V 0.014 184V+82A 0.015 184V+82A+54V+58E+46I+10F 0.015 108I+184V+82A+54V+58E+46I+10F 0.016 p8MJ4-HSC 0.014
Figure 5.2 Standardization of pseudoviral titres. (A) HIV-1 RT ELISA calibration
curve. (B) HIV-1 RT concentrations from pseudovirus produced from recombinant gag-pol/patient PR-RT expression vectors. p8MJ4-HSC was the original expression vector. -2.0 -1.5 -1.0 -0.5 0.0
0
2
4
6
8
A
bs
or
ba
nc
e
(A
40 5n m)
195
References
1. Prevention CfDCa. Current Trends Update on Acquired Immune Deficiency Syndrome (AIDS) -- United States. Morbidity and Mortality Weekly
1982,31:507-508.
2. F B-S, JC C, F R, MT N, S C, J G, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983,220:868-871.
3. JA L, AD H, SM K, JA L, JM S, LS O. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984,225:840- 842.
4. Coffin J, Haase A, Levy J, Montagnier L, Oroszlan S, Teich N, et al. What to call the AIDS virus? Nature 1986,321:10.
5. Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000,288:1789-1796. 6. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, et al.
Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999,397:436-441.
7. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. Aids 2006,20:W13- W23.
8. Vallari A, Bodelle P, Ngansop C, Makamche F, Ndembi N, Mbanya D, et al. Four new HIV-1 group N isolates from Cameroon: Prevalence continues to be low. AIDS Res Hum Retroviruses 2010,26:109-115.
196
9. Peeters M, Gueye A, Mboup S, Bibollet-Ruche F, Ekaza E, Mulanga C, et
al. Geographical distribution of HIV-1 group O viruses in Africa. Aids
1997,11:493-498.
10. Plantier J-C, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, et
al. A new human immunodeficiency virus derived from gorillas. Nature medicine 2009,15:871-872.
11. Hemelaar J Fau - Gouws E, Gouws E Fau - Ghys PD, Ghys Pd Fau - Osmanov S, Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007.
12. Vidal N, Mulanga C, Bazepeo SE, Mwamba JK, Tshimpaka J-W, Kashi M, et
al. Distribution of HIV-1 variants in the Democratic Republic of Congo
suggests increase of subtype C in Kinshasa between 1997 and 2002. JAIDS
Journal of Acquired Immune Deficiency Syndromes 2005,40:456-462.
13. Soares EA, Martínez AM, Souza TM, Santos AF, Da Hora V, Silveira J, et al. HIV-1 subtype C dissemination in southern Brazil. Aids 2005,19:S81-S86. 14. Luo C-C, Tian C, Hu D, Kai M, Dondero T, Zheng X. HIV-1 subtype C in
China. The Lancet 1995,345:1051-1052.
15. Piyasirisilp S, McCutchan FE, Carr JK, Sanders-Buell E, Liu W, Chen J, et al. A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol 2000,74:11286-11295.
16. Hahn BH, Shaw GM, De KM, Sharp PM. AIDS as a zoonosis: scientific and public health implications. Science 2000,287:607-614.
197
17. Kanki P, De Cock K. Epidemiology and natural history of HIV-2. AIDS-
LONDON-CURRENT SCIENCE THEN RAPID SCIENCE PUBLISHERS THEN LIPPINCOTT RAVEN- 1994,8:S85-S85.
18. Control CfD. Factsheet HIV Type 2. 2010.
19. Gao F, Yue L, Robertson DL, Hill SC, Hui H, Biggar RJ, et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol 1994,68:7433- 7447.
20. Chen Z, Luckay A, Sodora DL, Telfer P, Reed P, Gettie A, et al. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian
immunodeficiency virus-infected sooty mangabeys. J Virol 1997,71:3953- 3960.
21. Aguchi JY, Devare SG, Brennan CA. Sequence Note: Identification of a New HIV-2 Subtype Based on Phylogenetic Analysis of Full-Length Genomic Sequence. AIDS Res Hum Retroviruses 2000,16:925-930.
22. Damond F, Worobey M, Campa P, Farfara I, Colin G, Matheron S, et al. Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. AIDS Res Hum Retroviruses 2004,20:666-672. 23. Lemey P, Pybus OG, Wang B, Saksena NK, Salemi M, Vandamme A-M.
Tracing the origin and history of the HIV-2 epidemic. Proceedings of the
National Academy of Sciences 2003,100:6588-6592.
24. Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends in
198
25. UNAIDS. UNAIDS report on the global AIDS epidemic. UNAIDS Global
Report 2012.
26. Shannon KM, Ammann AJ. Acquired immune deficiency syndrome in childhood. The Journal of pediatrics 1985,106:332-342.
27. Organization WH. HIV/AIDS Data Products: Size of the Epidemic. Global
Health Observatory 2011.
28. Organization WH. Antiretroviral therapy of HIV infection in infants and children: towards universal access. 2010,Annex E.
29. UNAIDS. The Gap Report. 2013.
30. Paintsil E, Andiman WA. Care and management of the infant of the HIV-1- infected mother. In: Seminars in perinatology: Elsevier; 2007. pp. 112-123. 31. De Cock K, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al.
Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000,283:1175-1182. 32. Lehman DA, Farquhar C. Biological mechanisms of vertical human
immunodeficiency virus (HIV‐1) transmission. Reviews in medical virology 2007,17:381-403.
33. Dunn D, Newell M, Mayaux M, Kind C, Goedert J, Andiman W, et al. Mode of delivery and vertical transmission of HIV-1: a review of prospective studies. JAIDS Journal of Acquired Immune Deficiency Syndromes 1994,7:1064-1066.
34. Dunn DT, Newell M-L, Ades A, Peckham CS. Risk of human
immunodeficiency virus type 1 transmission through breastfeeding. The
199
35. UNAIDS. UNGASS Declaration: Resolution adopted by the General Assembly; Declaration of Commitment on HIV/AIDS. 2001.
36. Taha TE, Kumwenda NI, Gibbons A, Broadhead RL, Fiscus S, Lema V, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. The Lancet
2003,362:1171-1177.
37. Taha TE, Kumwenda NI, Hoover DR, Fiscus SA, Kafulafula G, Nkhoma C, et
al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV
in an African setting: a randomized controlled trial. Jama 2004,292:202-209. 38. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al.
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. The Lancet 1999,354:795-802.
39. Organization WH. Prevention of mother-to-child transmission of HIV: Selection and use of Nevirapine - Technical Notes. Geneva 2001.
40. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. The Lancet
2003,362:859-868.
41. Bedri A, Gudetta B, Isehak A, Kumbi S, Lulseged S, Mengistu Y, et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008,372:300-313.
200
42. Kumwenda NI, Hoover DR, Mofenson LM, Thigpen MC, Kafulafula G, Li Q, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. New England Journal of Medicine 2008,359:119-129.
43. Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP, et al. Maternal or infant antiretroviral drugs to reduce HIV-1
transmission. New England Journal of Medicine 2010,362:2271-2281. 44. (WHO) WHO. 2010 Antiretroviral drugs for treating pregnant women and
preventing HIV infection in infants in resource-limited settings: Towards universal access. Recommendations for a public health approach. WHO HIV
PMTCT treatment guidelines 2010.
45. Organization WH. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. World Health Organization
Programmatic Update 2013,WHO/HIV/2012.6.
46. WHO, UNICEF, UNAIDS. Progress report 2011: Global HIV/AIDS response. 2011.
47. HIV/AIDS WHO. Treatment of children living with HIV: Latest updates. 2011.
48. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC,
Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine 2011,365:493-505.
49. Shapiro RL, Thior I, Gilbert PB, Lockman S, Wester C, Smeaton LM, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. Aids 2006,20:1281-1288.